source
- Sanofi halts development of Nurix-partnered STAT6 degrader, triggering sharp drop in Nurix stockSanofi announced it is ending work on SAR448272, an experimental oral drug that was intended to degrade the STAT6 protein, which is linked to inflammatory diseases. The biotech firm Nurix, which l…
- China rises on biotech risk list as US draft rules threaten Chinese biopharma investmentsA recent Signal Survey shows China moving up the biotech industry’s concern list even before the Treasury Department issued draft rules that could curb U.S. investment in Chinese biopharma. The pr…